 SOUTH PLAINFIELD, N.J., March 30, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT today announced that the European Commission EC has granted marketing authorization to EvrysdiTM risdiplam for the treatment of spinal muscular atrophy SMA in patients 2 months and older. 